case_images: PMC3090772_01
case_images: A 53-year-old man had a 2-month history of visual loss to 20/60 in his right eye. We had performed panretinal photocoagulation (PRP) in his right eye 2 years previously. Fundus examination revealed a mild vitreous hemorrhage. (a) Fluorescein leakage from neovascularization of the disc (NVD) at baseline between retinal vessels crossing the optic disc was demonstrated. In addition, fluorescein angiography (FA) showed magnification of retinal neovascularization elsewhere (NVE) in the superonasal retina. (b) At week 1 after intravitreal bevacizumab, total resolution of leakage from NVD and NVE are shown. His visual acuity returned to 20/32 one month later. He needed a reinjection at months 6, 14, and 24 of followup. A PRP was performed at 24 months.
case_images: JOP2011-584238.004.jpg
case_images: PMC3090772_01_JOP2011-584238.004.jpg
case_images: fig4
case_images: When divided by type of RN, of the total of 43 eyes, 15 (34.9%) eyes showed total regression of NVE (neovascularization elsewhere) on fundus examination with absence of fluorescein leakage, (Figure 4), 10 (23.3%) eyes demonstrated partial regression of NVE on fundus examination and FA, and twelve (27.9%) eyes showed no regression of NVE.
case_images: (a)-(c) Color photographs before intravitreal bevacizumab. Severe proliferative diabetic retinopathy with abundant fibrovascular tissue and subhyaloid hemorrhage. The retina is attached and best-corrected visual acuity (BCVA) is 20/80. (d)-(f) Color photographs 10 days after 2.5 mg of intravitreal bevacizumab demonstrating dense fibrous tissue contraction, and tractional retinal detachment with macular involvement. BCVA is hand motions at 2 meters. (g)-(i) Same eye, eight days after vitrectomy. The retina is reattached and best-corrected visual acuity (BCVA) is 20/120 with silicone oil tamponade.
case_images: JOP2011-584238.005.jpg
case_images: PMC3090772_01_JOP2011-584238.005.jpg
case_images: fig5
case_images: Twenty-five (3.2%) eyes (patients) out of 698 IVT injections developed or had progression of TRD, (Figure 5).